Hua Medicine ("the Company", HKEX Stock Code: 2552) announced today that dorzagliatin (trade name: MYHOMSIS®, 華領片®), the Company's first-in-class glucosekinase activator (GKA), has been dispensed its first prescription in Hong Kong.
Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552) announced today that it has entered a scientific research collaboration agreement with GemVCare (referred to as GVC), a Hong Kong-based biotechnology enterprise. Leveraging their respective core strengths, the two parties will conduct joint clinical trial and real-world research using dorzagliatin (trade name: MYHOMSIS®, 華領片®)
Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552) announced today that its global first-in-class glucokinase activator (GKA) dorzagliatin (trade name in Macao: MYHOMSIS®, 華領片®) has been approved for marketing by the Pharmaceutical Administration Bureau of the Macao Special Administrative Region for the treatment of Type 2 diabetes in adults.
ir@huamedicine.com
No.275 Ai Di Sheng Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203
沪公网安备 31011502013809号 Privacy Statement Terms of Use
